1. EHL Technologies in Hemophilia Care

3. Background

4. PEGylation of Factor VIII

5. Fc Fusion of Factor VIII

6. Immunogenicity of Factor VIII

7. Fc-Dependent Immunomodulatory Effector Pathways

8. The Role of Regulatory T Cells

9. Immunomodulatory Effect of Fc

10. Individualizing Therapy in Hemophilia Care

11. Pharmacokinetic Response to Factor VIII Varies Between Patients

12. Treatment Targets

13. Parameters for Selecting the Right Treatment

14. Key Advantages of New Agents With EHL

15. Pivotal Clinical Trials of EHL Factor VIIIs

16. Dosing Regimens in Prophylactic Trial Arms

17. Results: Median ABR

18. Results: Zero ABR

19. Effect of Duration of Treatment on ABR and QoL

20. Safety Outcomes

21. Key Messages From Trials

22. Key Messages From Trials (cont)

23. Switching From Conventional Therapy to EHL Agents

24. Switching From Conventional Therapy to EHL Agents (cont)

25. Summary

26. Abbreviations